Background: Chondramides are cyclodepsipeptides produced by strains of the myxobacterium, Chondromyces crocatus. These peptides, which have been reported to inhibit yeast and mammalian cell proliferation, are related to jasplakinolide, which has been isolated from marine sponges of the genus Jaspis and has been shown to interfere with the actin cytoskeleton (a structural component of cells that helps maintain their shape and is involved in processes, such as cell division and cell locomotion). We studied the effects of the chondramides (A, B, C, and D) on tumor cell growth, on cytoskeletal structure, and on actin polymerization in vitro and compared these effects with those of cytochalasin D and jasplakinolide. Methods: Cell proliferation was measured by means of tetrazolium salt reduction assays. Effects on the cytoskeleton were studied by use of fluorescence techniques, and actin polymerization in vitro was measured by means of viscosimetry. Results: Proliferation of tested tumor cell lines was inhibited by the chondramides. Concentrations that inhibited proliferation by 50% (IC 50 values) ranged from 3 to 85 nM and were of the same order of magnitude as those found for cytochalasin D and jasplakinolide. Fluorescence staining of potoroo cells incubated with chondramides A and B showed that organization of the actin cytoskeleton was disrupted; however, the microtubule system was not affected. Viscosimetric measurement showed that, depending on the experimental conditions, chondramide A induced or accelerated actin polymerization in vitro. Conclusion:
The chondramides-unlike jasplakinolide-can be produced in large amounts by fermentation, and, similar to jasplakinolide, they appear to have antiproliferative activity against carcinoma cell lines by targeting the actin cytoskeleton. [J Natl Cancer Inst 1998; 90:1559-63]
The chondramides are cyclodepsipeptides produced by strains of the myxobacterium, Chondromyces crocatus (1) . The structures of the four chondramides published so far (2) are related to jasplakinolide (3), also known as jaspamide (4) (Fig.  1 ), which has been isolated from marine sponges of the genus Jaspis and related genera (5) . Besides different substituents, the chondramides have an 18-membered macrocyclic ring instead of the 19-membered ring system of jasplakinolide. Both compounds inhibit the growth of yeasts and show cytostatic activities against cultivated mammalian cells. Jasplakinolide has been reported to induce actin polymerization in vitro (6) and a disruption of the actin skeleton in vivo (7) . Here we report on the effects of the chondramides on the growth of tumor cells, on the cytoskeleton, and on actin polymerization in vitro. We compare the effects with those of cytochalasin D and jasplakinolide.
MATERIALS AND METHODS
Materials. Cell lines were obtained from the American Type Culture Collection (Manassas, VA) (Pt K2 and SK-OV-3) or the Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany) (A-431, A-498, A-549, KB-3.1, L-929, and U-937). Actin was prepared from rabbit skeletal muscle as described (8) . Jasplakinolide and Alexa 488 phalloidin were purchased from Molecular Probes, Inc. (Eugene, OR) and WST-1 was purchased from Boehringer Mannheim (Mannheim, Germany). Other reagents including antibodies were from Sigma Chemical Co. (Deisenhofen, Germany). All tissue culture reagents and tablets to prepare phosphate-buffered saline (PBS) were obtained from Life Technologies Inc. (GIBCO BRL) (Eggenstein, Germany). Plasticware was from Nunc Inc. (Roskilde, Denmark).
Growth inhibition assay. The tumor cell lines were cultivated in the media recommended by the supplier plus 10% newborn calf serum (NCS) or fetal calf serum (FCS; SK-OV-3 cells) at 37°C and 10% CO 2 in a moist atmosphere. Growth inhibition was measured in microplates. Aliquots of 120 L of the suspended tumor cells (50 000/mL) were given to 60 L of a serial dilution of the inhibitor. As a parameter of growth, we measured the reduction of M T T ( 3 -[ 4 , 5 -d i m e t h y l t h i a z o l -2 -y l ] -2 , 5 -diphenyltetrazolium bromide) (9) or, in the case of U-937 cells, that of WST-1 (see supplier's instruction) after an incubation period of 5-13 days, when the control cells (to which only the solvent methanol had been added) reached confluency or entered the stationary growth phase.
Fluorescence staining. Pt K2 potoroo cells were seeded into four-well plates with glass coverslips (13 mm in diameter) at the bottom of the wells. Minimum essential medium with nonessential amino acids (MEM; Life Technologies, Inc.) was used plus 10% FCS. Exponentially growing cells were incubated with the inhibitor for different periods of time. Cells were fixed with 3.7% formaldehyde in PBS for 10 minutes, made permeable by a 5-minute treatment with 0.1% Triton X-100 in PBS, and were then incubated for 1 hour with tetramethylrhodamine isothiocyanate (TRITC) conjugated phalloidin (1 g/mL) at 37°C. For indirect immunostainings, the cells were first incubated with primary monoclonal antibodies (anti-␣-tubulin, 1:500; anti-tropomyosin, 1:200) and then with a secondary anti-mouse immunoglobulin G antibody conjugated with TRITC (1:100). Cells were always rinsed with PBS between two incubations. The coverslips were mounted in Vectashield containing DAPI (Vector Laboratories, Inc., Burlingame, CA) and examined using a Zeiss Axiophot fluorescence microscope, Carl Zeiss Jena GmbH, Jena, Germany. We used phalloidin conjugated with Alexa 488 instead of TRITC in triple stainings. Human KB-3.1 cervix carcinoma cells were cultured in titerplates using Dulbecco's modified Eagle medium (DME; Life Technologies, Inc.) plus 10% NCS and stained for F-actin in the same way. The intensity of the TRITC fluorescence in the wells was measured at 615 nm, with an excitation at 530 nm using a Victor 1420 Multilabel Counter (Wallac, Turku, Finland).
Competitive binding between TRITCphalloidin and chondramide. Actin (final concentration 1.1 M), polymerized with 2 mM MgCl 2 in imidazole buffer (10 M imidazole, 50 mM KCl, 0.2 mM adenosine triphosphate [ATP], pH 7.0) for 2 hours, was incubated with TRITC-phalloidin (final concentration, 0.8 M) and serial dilutions of various inhibitors in titerplates. The fluorescence intensity was measured after 3 hours as described above. 
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RESULTS
Antiproliferative Effect on Tumor Cell Lines
The chondramides have been reported to be potent inhibitors of mammalian cells (1) . To confirm and extend these results, we studied the growth inhibition of five tumor cell lines of different origins in comparison with jasplakinolide and cytochalasin D. As shown in Table 1 , the chondramides inhibited the growth of all tumor cell lines tested. The concentrations that inhibited cell growth by 50% ranged from 3 to 85 nM and were in the same order of magnitude as those found for jasplakinolide and cytochalasin D.
Visual inspection under the microscope showed that at concentrations near the IC 50 -value, adherent cells had increased in size and often contained two or more nuclei. As checked with L-929 mouse fibroblasts, these multinucleated cells persisted after drug removal.
Effects on the Cytoskeleton
The influence of chondramide A and B, jasplakinolide, and cytochalasin D on the cytoskeleton was investigated in Pt K2 potoroo cells by labeling with TRITC-phalloidin, which specifically binds to F-actin, and with antibodies against ␣-tubulin and tropomyosin (Fig.  2) . While the microtubuli network was not affected, the actin skeleton showed striking alteration with all four inhibitors. In general, the stress fibers became reduced and finally disappeared completely. Instead of them, we observed an increasing diffuse F-actin fluorescence, particularly in the center of the cells, as well as lumps of F-actin. The changes began to be visible after 1 hour of exposure and were fully expressed after 1 day. While the effects of the chondramides could not be distinguished from those of jasplakinolide, both differed from those of cytochalasin D. With the chondramides and jasplakinolide, we observed a reduced number of stress fibers after 1 hour, but these looked stronger than in the control cells and after 2 hours often developed knots. After 4 hours, almost all fibers had disappeared. We did not see these strong, knotty fibers with cytochalasin D. The few actin filaments that were still present after 1 hour looked more like those in the control cells. Instead of the filaments, many fluorescent spots emerged. Only triangular spots remained of the original actin skeleton representing the adhesion plaques in the surface of the cells. When staining the tropomyosin of the cells, we observed an even more striking difference between chondramide and cytochalasin D. With chondramide and jasplakinolide, the transformation of the tropomyosin resembled that of the actin network. Staining tropomyosin and actin with different colors, we could prove that both the tropomyosin and the actin lumps had the same positions in the cells. No changes in the tropomyosin filaments were visible with cytochalasin D.
When we measured the fluorescence intensity of TRITC-phalloidin-labeled KB-3.1 cells after treatment with the chondramides or jasplakinolide in titerplates, we did not find a decrease of the F-actin label in the wells. In detailed studies with chondramide B (100 ng/mL), we measured a 20% increase of F-actin in the cells after 24 hours. Under the microscope, we observed that the cells contained very large lumps of F-actin, often only one lump per cell. When we exchanged the culture medium with chondramide after 1 day of incubation for fresh medium without the inhibitor, we saw newly formed normal actin fibers 24 hours later, but the lumps were still present.
In Vitro Effects on Actin
Actin polymerization in vitro was followed by viscosimetric measurements. *Cells were seeded with serial dilutions of the indicated compounds. Growth inhibition was determined by tetrazolium salt reduction assays. IC 50 values ‫ס‬ concentrations at which the reduction of tetrazolium dye is reduced by 50% of the control without drug.
We investigated the influence of chondramide A under polymerizing and nonpolymerizing conditions (Fig. 3, A and  B) . When we induced actin polymerization with 2 mM MgCl 2 , a maximum steady-state viscosity of 0.3 was reached after 15 minutes. Under the same conditions, but in the presence of chondramide A in a concentration range of 0.01-1 M, the viscosity of 0.3 was reached within 5-10 minutes. A concentration of 30 M led to a higher viscosity than was reached with the salt alone.
Under nonpolymerizing, low-salt conditions (0.2 mM MgCl 2 ), chondramide was able to induce an actin polymerization that was comparable to that with 2 mM MgCl 2 , but the maximum viscosities reached were lower, even after the addition of 20 M chondramide A. With phalloidin under the same conditions, we found neither an induction nor an acceleration of the actin polymerization.
Jasplakinolide has been reported to bind to F-actin competitively to rhodamine-phalloidin (6). We performed binding experiments with chondramide A, phalloidin, cytochalasin D, and TRITCphalloidin (Fig. 3, C) and found that both chondramide A and phalloidin competed to the same extent for the binding site of TRITC-phalloidin. The competition curves were nearly identical. Cytochalasin D did not compete.
DISCUSSION
After epothilon (10, 11) and rhizopodin (12) , the chondramides are the third class of compounds from myxobacteria that act on the cytoskeleton. While epothilon interacts with tubulin, rhizopodin and chondramides interfere with the actin system. A first hint at the mechanism of action of chondramide was the observation that the compound induced the formation of large, multinucleated cells. The same was reported for cytochalasin (13) and more recently for jasplakinolide (7) . All three compounds allow division of the nuclei, but not cell cleavage.
When we studied the actin cytoskeleton by fluorescence staining, we observed a disappearance of actin filaments in all three cases, but there were differences between cytochalasin D on the one side and chondramide and jasplakinolide on the other. The effects of the latter two on the actin network could not be distinguished.
W h e n m e a s u r i n g t h e T R I T Cphalloidin fluorescence of cells that were treated with the chondramides or jasplakinolide and fixed in situ, we did not observe any decrease of F-actin. The destruction of the normal actin network seen under the microscope is obviously not accompanied by a general actin depolymerization. In fact, we recognized a slight increase of diffuse F-actin in the cells with the chondramides or jasplakinolide as well as the appearance of large lumps of F-actin. In contrast, a decrease of bound rhodamine-phalloidin was measured in cell extracts of PC-3 prostate cells as early as 1 hour after the addition of jasplakinolide (7) . The difference to our results with chondramide could be due to differences in the experimental systems. An increase of F-actin was also reported after treatment of human leukocytes with cytochalasins (14) .
The in vitro experiments showed that the mechanism of action of chondramide differs from that of cytochalasin D. The cytochalasins are known to inhibit actin polymerization by binding to the plus end of F-actin (15) . Under polymerizing salt conditions, high concentrations of cytochalasin D led to an acceleration of actin polymerization with respect to the control, but the steady-state viscosities reached were clearly lower (16) . At inducing salt concentrations, chondramide accelerated polymerization, and high chondramide concentrations led to a higher degree of actin polymerization than could be reached by the salt alone. Unlike cytochalasin D, chondramide A induced polymerization under low salt conditions. The same was reported for jasplakinolide (6) .
While the in vitro effects of cytochalasin D differed clearly from those of chondramide and jasplakinolide, similar morphologic changes were observed in vivo. In both cases, the actin filaments finally disappeared. But the strong, knotty fibers observed soon after incubation with the chondramides or with jasplakinolide and the very large lumps of F-actin as the final effect were not seen with cytochalasin D. The difference between the two types of inhibitors became even clearer when we labeled the tropomyosin filaments, which are closely connected to the actin fibers. While cytochalasin D led to a degradation of actin filaments, it obviously did not impair the tropomyosin filaments. With the chondramides and jasplakinolide, we found the same changes in the tropomyosin and the actin skeleton. We assume that, also in vivo, the actin filaments are not degraded, but rather hyperpolymerize to form big lumps, and that the actin-bound tropomyosin filaments simply follow those organizational changes.
Binding studies showed that chondramide A competes with TRITCphalloidin to the same extent as does phalloidin. The same was found when the competition experiments were performed with [
3 H]-demethyl phalloidin (Faulstich H: personal communication). Competition with rhodamine-phalloidin was also reported for jasplakinolide (6) . There was no competition between cytochalasin D and chondramide for the binding site on F-actin.
In contrast to phalloidin, which normally does not penetrate intact cells, jasplakinolide and the chondramides had cytotoxic effects in all cell lines tested. Both groups of compounds might therefore be useful as chemotherapeutic agents. Investigations on the effect of jaspamide on leukemic cells and on blast cells of acute myeloid leukemia patients were promising (17) . 
